What is eNOS?
eNOS (endothelial nitric oxide synthase, gene symbol NOS3) is the enzyme that catalyses production of nitric oxide from L-arginine in vascular endothelial cells. eNOS activation downstream of Akt is the terminal step in the most-cited BPC-157 mechanistic cascade.
What the research literature says
eNOS is one of three nitric oxide synthase isoforms (alongside neuronal NOS and inducible NOS). Constitutively expressed on the vascular endothelium, eNOS catalyses the five-electron oxidation of L-arginine to L-citrulline with release of nitric oxide (NO) gas. Released NO diffuses to underlying vascular smooth muscle where it activates soluble guanylate cyclase, raises cyclic GMP, and produces vasodilation.
Regulation occurs at three levels: gene expression (slow), post-translational modification (fast), and substrate/cofactor availability. The acute regulatory step for the BPC-157 literature is Akt-mediated phosphorylation on Ser1177, which raises catalytic activity within minutes of receptor engagement upstream. The Hsieh angiogenic-mechanism work documents the cascade in vascular endothelial cell culture (PMID 27847966); the Sikiric nitric-oxide-system synthesis covers the broader BPC-157 framework (PMID 23755725).
The detailed coverage of eNOS’s role in peptide-research signalling is in the eNOS glossary entry.
Why this matters in research context
eNOS matters in peptide-research contexts as the terminal enzymatic step that converts VEGFR2-Akt cascade activation into the diffusible nitric oxide signalling that drives vasodilation, platelet inhibition, and the broader vascular-function framework. Researchers studying BPC-157’s vascular pharmacology should expect to see eNOS-axis engagement as the downstream output. NO output is measured directly by Griess assay or fluorescent NO-sensitive probes (DAF-2, DAF-FM), and the eNOS-pathway contribution to an observed effect is established by pharmacological NO-synthase inhibition (L-NAME or L-NMMA) — when the inhibitor abolishes the functional outcome, the eNOS axis is implicated as causal in the observed pharmacology.
Related compounds
- BPC-157 10mg — terminal eNOS-driven NO output in mechanism
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des 2014;20(7):1126-1135. [PMID 23755725]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.